Eyepoint Pharmaceuticals (EYPT) Upgraded to “Buy” by ValuEngine
ValuEngine upgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a hold rating to a buy rating in a report published on Wednesday.
EYPT has been the topic of several other research reports. HC Wainwright reaffirmed a buy rating and issued a $2.75 price objective on shares of Eyepoint Pharmaceuticals in a research report on Thursday, September 13th. Zacks Investment Research lowered shares of Eyepoint Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, September 17th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Eyepoint Pharmaceuticals has a consensus rating of Buy and a consensus price target of $4.85.
Eyepoint Pharmaceuticals stock opened at $2.60 on Wednesday. Eyepoint Pharmaceuticals has a fifty-two week low of $0.93 and a fifty-two week high of $2.88. The company has a debt-to-equity ratio of 1.48, a quick ratio of 0.83 and a current ratio of 1.84.
A number of hedge funds have recently made changes to their positions in EYPT. FineMark National Bank & Trust bought a new stake in Eyepoint Pharmaceuticals in the second quarter worth about $118,000. California Public Employees Retirement System bought a new stake in Eyepoint Pharmaceuticals in the second quarter worth about $135,000. Creative Planning bought a new stake in Eyepoint Pharmaceuticals in the second quarter worth about $162,000. Essex Investment Management Co. LLC bought a new stake in Eyepoint Pharmaceuticals in the second quarter worth about $170,000. Finally, Bard Associates Inc. bought a new stake in Eyepoint Pharmaceuticals in the second quarter worth about $189,000. 62.93% of the stock is currently owned by institutional investors and hedge funds.
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.
Further Reading: Trading Strategy Methods for Individual Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.